Roivant Sciences stock price target raised to $24 by Goldman Sachs
PositiveFinancial Markets

Goldman Sachs has raised its stock price target for Roivant Sciences to $24, reflecting confidence in the company's growth potential. This adjustment is significant as it indicates a positive outlook for investors and suggests that Roivant is on a promising trajectory in the biotech sector.
— Curated by the World Pulse Now AI Editorial System